Tellgen Corporation (SHE:300642)

China · Delayed Price · Currency is CNY

18.50

-1.22 (-6.19%)

Oct 19, 2026, 3:04 PM CST

Market Cap	2.95B -34.8%
Revenue (ttm)	392.11M +3.1%
Net Income	12.31M -59.9%
EPS	0.08 -60.0%
Shares Out	159.59M
PE Ratio	244.52
Forward PE	n/a
Dividend	0.05 (0.27%)
Ex-Dividend Date	Sep 3, 2026

Volume	21,662,900
Open	18.89
Previous Close	19.72
Day's Range	17.74 - 19.48
52-Week Range	11.04 - 30.00
Beta	0.32
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 27, 2026

About Tellgen

Tellgen Corporation research, development, production, and sales of in-vitro diagnostic products in China and internationally. The company offers fully automatic flow fluorescence analyzer and CLIA analyzer; molecular test such as HPV test, lung cancer, colon cancer, personalized medicine, and infertility; and automatic integrated gene detection systems. It also provides tumor detection products; HPV nucleic acid testing products; methylation mutation detection products; detection products for invasive fungal diseases. The company was founded i... [Read more]

Industry Medical Devices

Sector Healthcare

Founded 2003

Employees 683

Stock Exchange Shenzhen Stock Exchange

Ticker Symbol 300642

Full Company Profile

Financial Performance

In 2025, Tellgen's revenue was 363.83 million, a decrease of -16.70% compared to the previous year's 436.78 million. Earnings were 3.59 million, a decrease of -89.61%.

Financial Statements